RSS Feeds
Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer
- Timothy J. Wilt, MD, MPH;
- Roderick MacDonald, MS;
- Indulis Rutks, BA;
- Tatyana A. Shamliyan, MD, MS;
- Brent C. Taylor, PhD; and
- Robert L. Kane, MD
- From the University of Minnesota School of Medicine, Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, and Clinical Outcomes Research Center, School of Public Health, Health Policy and Management, University of Minnesota, Minneapolis, Minnesota.
-
Appendix Figure 1. Study flow diagram.AUA = American Urological Association; RCT = randomized, controlled trial; RP = radical prostatectomy.
-
Figure 1. Overall survival at time points, by treatment, from nonrandomized studies.The symbol size is proportional to the number of patients: <50, 50–150, 150–300, or >300. Brachy = brachytherapy; C-EBRT = conformal external-beam radiation therapy, EBRT = external-beam radiation therapy; RP = radical prostatectomy; WW = watchful waiting.
-
Figure 2. Complications of brachytherapy, radical prostatectomy, external-beam radiation therapy, conformal external-beam radiation therapy, nerve-sparing radical prostatectomy, and watchful waiting from nonrandomized studies.The symbol size is proportional to the number of patients: <50, 50–150, 150–300, or >300.
-
Appendix Figure 2. Biochemical progression–free survival after cryotherapy or high-intensity focused ultrasonography among patients in nonrandomized clinical trials and case series.*Combined with transurethral resection of the prostate.
-
Appendix Figure 3. Clinical outcomes after laparoscopic radical prostatectomy, robotic-assisted radical prostatectomy, or intensity-modulated radiation therapy.PSA = prostate-specific antigen.
Related Clinical Content
